Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting
High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are...
Uložené v:
| Vydané v: | The American journal of surgical pathology Ročník 36; číslo 2; s. 242 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.02.2012
|
| Predmet: | |
| ISSN: | 1532-0979, 1532-0979 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are specific indications for use of immunohistochemistry for the somatostatin receptor subtype 2A, but this has up to now been limited by the lack of an adequate reliable antibody. The aim of this study was to correlate immunohistochemistry using the new monoclonal anti-somatostatin receptor subtype 2A antibody UMB-1 with the gold standard in vitro method quantifying somatostatin receptor levels in tumor tissues. A UMB-1 immunohistochemistry protocol was developed, and tumoral UMB-1 staining levels were compared with somatostatin receptor binding site levels quantified with in vitro I-[Tyr]-octreotide autoradiography in 89 tumors. This allowed defining an immunohistochemical staining threshold permitting to distinguish tumors with somatostatin receptor levels high enough for clinical applications from those with low receptor expression. The presence of >10% positive tumor cells correctly predicted high receptor levels in 95% of cases. In contrast, absence of UMB-1 staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. If 1% to 10% of tumor cells were stained, a weak staining intensity was suggestive of low somatostatin receptor levels. This study allows for the first time a reliable recommendation for eligibility of an individual patient for in vivo somatostatin receptor targeting based on somatostatin receptor immunohistochemistry. Under optimal methodological conditions, UMB-1 immunohistochemistry may be equivalent to in vitro receptor autoradiography. |
|---|---|
| AbstractList | High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are specific indications for use of immunohistochemistry for the somatostatin receptor subtype 2A, but this has up to now been limited by the lack of an adequate reliable antibody. The aim of this study was to correlate immunohistochemistry using the new monoclonal anti-somatostatin receptor subtype 2A antibody UMB-1 with the gold standard in vitro method quantifying somatostatin receptor levels in tumor tissues. A UMB-1 immunohistochemistry protocol was developed, and tumoral UMB-1 staining levels were compared with somatostatin receptor binding site levels quantified with in vitro I-[Tyr]-octreotide autoradiography in 89 tumors. This allowed defining an immunohistochemical staining threshold permitting to distinguish tumors with somatostatin receptor levels high enough for clinical applications from those with low receptor expression. The presence of >10% positive tumor cells correctly predicted high receptor levels in 95% of cases. In contrast, absence of UMB-1 staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. If 1% to 10% of tumor cells were stained, a weak staining intensity was suggestive of low somatostatin receptor levels. This study allows for the first time a reliable recommendation for eligibility of an individual patient for in vivo somatostatin receptor targeting based on somatostatin receptor immunohistochemistry. Under optimal methodological conditions, UMB-1 immunohistochemistry may be equivalent to in vitro receptor autoradiography. High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are specific indications for use of immunohistochemistry for the somatostatin receptor subtype 2A, but this has up to now been limited by the lack of an adequate reliable antibody. The aim of this study was to correlate immunohistochemistry using the new monoclonal anti-somatostatin receptor subtype 2A antibody UMB-1 with the gold standard in vitro method quantifying somatostatin receptor levels in tumor tissues. A UMB-1 immunohistochemistry protocol was developed, and tumoral UMB-1 staining levels were compared with somatostatin receptor binding site levels quantified with in vitro I-[Tyr]-octreotide autoradiography in 89 tumors. This allowed defining an immunohistochemical staining threshold permitting to distinguish tumors with somatostatin receptor levels high enough for clinical applications from those with low receptor expression. The presence of >10% positive tumor cells correctly predicted high receptor levels in 95% of cases. In contrast, absence of UMB-1 staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. If 1% to 10% of tumor cells were stained, a weak staining intensity was suggestive of low somatostatin receptor levels. This study allows for the first time a reliable recommendation for eligibility of an individual patient for in vivo somatostatin receptor targeting based on somatostatin receptor immunohistochemistry. Under optimal methodological conditions, UMB-1 immunohistochemistry may be equivalent to in vitro receptor autoradiography.High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain whether a tumor is suitable for in vivo somatostatin receptor targeting, its somatostatin receptor expression has to be determined. There are specific indications for use of immunohistochemistry for the somatostatin receptor subtype 2A, but this has up to now been limited by the lack of an adequate reliable antibody. The aim of this study was to correlate immunohistochemistry using the new monoclonal anti-somatostatin receptor subtype 2A antibody UMB-1 with the gold standard in vitro method quantifying somatostatin receptor levels in tumor tissues. A UMB-1 immunohistochemistry protocol was developed, and tumoral UMB-1 staining levels were compared with somatostatin receptor binding site levels quantified with in vitro I-[Tyr]-octreotide autoradiography in 89 tumors. This allowed defining an immunohistochemical staining threshold permitting to distinguish tumors with somatostatin receptor levels high enough for clinical applications from those with low receptor expression. The presence of >10% positive tumor cells correctly predicted high receptor levels in 95% of cases. In contrast, absence of UMB-1 staining truly reflected low or undetectable somatostatin receptor expression in 96% of tumors. If 1% to 10% of tumor cells were stained, a weak staining intensity was suggestive of low somatostatin receptor levels. This study allows for the first time a reliable recommendation for eligibility of an individual patient for in vivo somatostatin receptor targeting based on somatostatin receptor immunohistochemistry. Under optimal methodological conditions, UMB-1 immunohistochemistry may be equivalent to in vitro receptor autoradiography. |
| Author | Reubi, Jean Claude Waser, Beatrice Körner, Meike Schonbrunn, Agnes Perren, Aurel |
| Author_xml | – sequence: 1 givenname: Meike surname: Körner fullname: Körner, Meike organization: Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland – sequence: 2 givenname: Beatrice surname: Waser fullname: Waser, Beatrice – sequence: 3 givenname: Agnes surname: Schonbrunn fullname: Schonbrunn, Agnes – sequence: 4 givenname: Aurel surname: Perren fullname: Perren, Aurel – sequence: 5 givenname: Jean Claude surname: Reubi fullname: Reubi, Jean Claude |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22251942$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkEtLxDAUhYOMOA_9ByLZueqYpI-0y2HwBQMKo-uSJjczlSapTTrSn-K_teIILlydy72H73DuHE2ss4DQJSVLSgp-87zaLklFaAwxzVmsCNfxCZrRNGbReC8mf-Ypmnv_RghlOWVnaMoYS2mRsBn63DojgvNBhNriDiS0wXXY91UYWsBshWtjeuv2tQ9O7sGM2g2497XdYYEtfGDjrJONs6LBwoa6cmrAHhqQwePQG9f5EVcHUTWA9cgecw71wWH_b3IQ3Q7Gze4cnWrReLg46gK93t2-rB-izdP943q1iWTCeIgylVKlMlBVoTWkivNcJBknAAIUBaalijVJK5LTQhKe5JkEqqHgGdcsY4Qt0PUPt-3cew8-lGNHCU0jLLjelwXN8pSR4tt5dXT2lQFVtl1tRDeUv99kX1XNgE4 |
| CitedBy_id | crossref_primary_10_1097_PAT_0b013e32835bae76 crossref_primary_10_5507_bp_2015_058 crossref_primary_10_1159_000443172 crossref_primary_10_1007_s42000_021_00327_w crossref_primary_10_1038_s41598_019_39607_2 crossref_primary_10_1016_j_humpath_2018_11_020 crossref_primary_10_3390_cancers14010162 crossref_primary_10_1371_journal_pone_0172030 crossref_primary_10_3109_0284186X_2014_925577 crossref_primary_10_1016_j_tranon_2020_100801 crossref_primary_10_1111_bph_12551 crossref_primary_10_1007_s00259_016_3486_2 crossref_primary_10_1016_j_soc_2019_11_002 crossref_primary_10_1007_s00701_018_3575_z crossref_primary_10_1007_s00292_015_0015_1 crossref_primary_10_1016_j_eprac_2023_12_008 crossref_primary_10_3390_cancers14061478 crossref_primary_10_1007_s12020_018_1706_1 crossref_primary_10_1007_s12020_023_03595_1 crossref_primary_10_1007_s11307_015_0873_1 crossref_primary_10_3390_ijms26146551 crossref_primary_10_1007_s12022_018_9522_y crossref_primary_10_1007_s12022_020_09658_7 crossref_primary_10_1016_j_humpath_2014_11_012 crossref_primary_10_1097_MD_0000000000001281 crossref_primary_10_1159_000371804 crossref_primary_10_1002_cne_23912 crossref_primary_10_1016_j_prp_2020_153066 crossref_primary_10_1007_s00259_021_05587_7 crossref_primary_10_1369_0022155419856900 crossref_primary_10_1007_s11102_013_0494_0 crossref_primary_10_1016_j_mce_2012_08_008 crossref_primary_10_1007_s00292_015_0023_1 crossref_primary_10_1007_s00401_015_1459_3 crossref_primary_10_1097_RLU_0000000000003570 crossref_primary_10_1159_000493944 crossref_primary_10_1007_s00428_020_02815_7 crossref_primary_10_1159_000381062 crossref_primary_10_1245_s10434_024_16463_7 crossref_primary_10_1111_jdv_14769 crossref_primary_10_1159_000381061 crossref_primary_10_3390_cancers14030594 crossref_primary_10_1007_s00292_013_1888_5 crossref_primary_10_1016_j_beem_2016_02_002 crossref_primary_10_1016_j_eprac_2024_09_018 crossref_primary_10_1007_s42000_021_00333_y crossref_primary_10_1053_j_ajkd_2015_01_027 crossref_primary_10_1007_s40618_020_01335_0 crossref_primary_10_1007_s12020_014_0320_0 crossref_primary_10_1089_cbr_2020_4633 crossref_primary_10_1007_s11154_017_9428_x crossref_primary_10_1016_j_pathol_2017_10_024 crossref_primary_10_1038_modpathol_2016_217 crossref_primary_10_1016_j_yfrne_2013_07_005 crossref_primary_10_1111_his_14252 crossref_primary_10_1016_j_humpath_2013_07_016 crossref_primary_10_1007_s00432_019_03011_0 crossref_primary_10_1016_j_tips_2013_10_001 crossref_primary_10_1016_j_beem_2016_01_001 crossref_primary_10_1007_s00292_023_01276_4 crossref_primary_10_1111_apm_13297 crossref_primary_10_1007_s11102_018_00935_7 crossref_primary_10_1159_000517530 crossref_primary_10_1186_s13550_015_0106_2 crossref_primary_10_1111_jcmm_13440 crossref_primary_10_1038_modpathol_2014_113 crossref_primary_10_1016_j_humpath_2019_12_002 crossref_primary_10_1210_jc_2018_01931 crossref_primary_10_1530_EJE_15_0832 crossref_primary_10_1186_s12885_022_09839_z crossref_primary_10_1111_cen_12775 crossref_primary_10_1371_journal_pone_0170536 crossref_primary_10_3390_cancers13092035 crossref_primary_10_1016_j_clineuro_2020_105865 crossref_primary_10_1016_j_humpath_2017_11_008 crossref_primary_10_3390_ijms242015164 crossref_primary_10_1002_pros_22743 crossref_primary_10_3389_fonc_2022_996489 crossref_primary_10_1007_s00292_025_01415_z crossref_primary_10_1016_j_jss_2014_01_044 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/PAS.0b013e31823d07f3 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-0979 |
| ExternalDocumentID | 22251942 |
| Genre | Journal Article Comparative Study |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK032234 |
| GroupedDBID | --- .-D .3C .55 .GJ .Z2 01R 0R~ 123 1J1 23M 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 6J9 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACLDA ACNWC ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BOYCO BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IH2 IKREB IKYAY IN~ IPNFZ J5H JF7 JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B LID N4W N9A NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA ODZKP OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YOC ZFV ZGI ZXP ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c427t-6d51dd6edb9ffe5d778a4670eeaed1e2fcd3f05b0819c07486ce1fe9767f26202 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 103 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000299316800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-0979 |
| IngestDate | Mon Sep 08 06:10:33 EDT 2025 Sat May 31 02:13:26 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c427t-6d51dd6edb9ffe5d778a4670eeaed1e2fcd3f05b0819c07486ce1fe9767f26202 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 22251942 |
| PQID | 916852090 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_916852090 pubmed_primary_22251942 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-Feb 20120201 |
| PublicationDateYYYYMMDD | 2012-02-01 |
| PublicationDate_xml | – month: 02 year: 2012 text: 2012-Feb |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The American journal of surgical pathology |
| PublicationTitleAlternate | Am J Surg Pathol |
| PublicationYear | 2012 |
| SSID | ssj0012812 |
| Score | 2.3931837 |
| Snippet | High overexpression of somatostatin receptors in neuroendocrine tumors allows imaging and radiotherapy with radiolabeled somatostatin analogues. To ascertain... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 242 |
| SubjectTerms | Antibodies, Monoclonal Autoradiography Humans Immunohistochemistry Neoplasms - chemistry Neoplasms - pathology Receptors, Somatostatin - analysis Receptors, Somatostatin - immunology Retrospective Studies |
| Title | Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22251942 https://www.proquest.com/docview/916852090 |
| Volume | 36 |
| WOSCitedRecordID | wos000299316800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFfSmb5sA1auIsjk-oQlRcWlUqSL1ViRcUCeLSpJX4FP6WcRZ6AXHgkls8iT0eP8_2CLmlPNBuEggn8APmBFShHYxl6iQCz9ogll5KZUU2wUajeDrl4yY3p2jSKlubWBlqaYT1kfcQxsQ2ZcO9m787ljTKBlcbBo1N0vERyVilZtN1EIHGdbAz9KnjcsbbyjnOeuP-ZO0CpL50mfZ_x5jVWTPY_-dXHpC9BmRCv9aKQ7Kh8iOyM2zC6Mfkc2IQqBpbTJTlgDZPzfHqDcUytR5ZoH3IbNmIqZoRi5YSDmyO_AskgEgcUJIRrxbGA65Nlhr5AUXFqVNAuXwziwKHy0pbmAWIiwHlrLKVgeJHyXU-Oo5-Qp4HD0_3j07D0eCIgLLSiWToSRkpmXKtVSgZixO0va5SiZKeolpIX7thapGHQLgSR0J5WiEIYtr2wqenZCs3uTonQF0hBBruyLbg97VOeCw4l6GIhM_cJO0SaOd8hv9tAxtJrsyymH3Pepec1es2m9e9Omb2OuvxgF78_fIl2UU0ROuU7CvS0bj_1TXZFqsyKxY3lW7hczQefgEsCN6h |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Somatostatin+receptor+subtype+2A+immunohistochemistry+using+a+new+monoclonal+antibody+selects+tumors+suitable+for+in+vivo+somatostatin+receptor+targeting&rft.jtitle=The+American+journal+of+surgical+pathology&rft.au=K%C3%B6rner%2C+Meike&rft.au=Waser%2C+Beatrice&rft.au=Schonbrunn%2C+Agnes&rft.au=Perren%2C+Aurel&rft.date=2012-02-01&rft.issn=1532-0979&rft.eissn=1532-0979&rft.volume=36&rft.issue=2&rft.spage=242&rft_id=info:doi/10.1097%2FPAS.0b013e31823d07f3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-0979&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-0979&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-0979&client=summon |